Kodiak Sciences: Zenkuda and tabirafusp-ted meet primary endpoints in Phase 3 DAYBREAK

Kodiak Sciences announced Zenkuda and tabirafusp-ted met primary endpoints in the Phase 3 DAYBREAK trial for wet AMD.Key Highlights:Original SEC Filing: Kodiak Sciences Inc. [ KOD ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important informa…